Document:

EX-10.2

 Exhibit 10.2 
  

 
 CONSULTING SERVICES AGREEMENT 

THIS CONSULTING SERVICES AGREEMENT (this
“Agreement”), effective as of October 13, 2022, is between INVIVYD, INC. a Delaware corporation having a place of business at 1601 Trapelo Road, Suite 178, Waltham, MA 02451, and its
successors or assignees (“Invivyd” or the “Company”) and Fred Driscoll, having a place of business at [***] (“Consultant”). 

WHEREAS, Invivyd desires to retain Consultant as an independent contractor to perform
consulting services for Invivyd as further detailed herein; and 
 WHEREAS, Consultant is
willing to perform the services, on the terms and conditions set forth below. 
 NOW, THEREFORE,
in consideration of the mutual promises contained herein, the parties agree as follows: 
 1. ENGAGEMENT OF
SERVICES. Consultant will provide financial consulting for the Company (the “Services”), as more fully described in a written Statement of Work made and agreed to by Company and Consultant from time to time during
the term of this Agreement, in the format attached hereto as Exhibit A (each, a “SOW”). To the extent a SOW is not inconsistent with this Agreement, and after acceptance by Company, each such SOW shall be deemed incorporated
into this Agreement with respect to scope of work, time for performance and cost of Services only. Consultant agrees to exercise diligence and the highest degree of professionalism in providing Services under this Agreement. Consultant shall perform
all Services in compliance with all Applicable Laws. “Applicable Laws” means the laws, statutes, rules, or regulations applicable to a party’s activities to be performed under this Agreement including, but not limited to, the
Federal Food, Drug, and Cosmetic Act, the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)), the Federal Civil Monetary Penalties Law (42 U.S.C. §
1320a-7a), the civil False Claims Act (31 U.S.C. §§ 3729 et seq.), the criminal False Claims Law (42 U.S.C. § 1320a- 7b(a)), the criminal Health Care Fraud laws (18 U.S.C. §§ 286, 287,
1347, 1349), the Patient Protection and Affordable Care Act of 2010 (42 U.S.C, § 18001 et seq.), the Federal Sunshine Law, the Generic Drug Enforcement Act of 1992 (21 U.S.C. § 335a et seq.), the Health Insurance Portability and
Accountability Act of 1996 (42 U.S.C. §§ 1320d et seq.) as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. §§ 17921 et seq.), the exclusion laws (42 U.S.C. § 1320a-7), Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act), the U.S. Foreign Corrupt Practices Act and any other anti-bribery and anti-corruption laws, state and
federal licensure laws, the regulations promulgated pursuant to such laws, and any other similar state or federal law. 
 2. COMPENSATION;
EXPENSES. 
 2.1 Compensation for Services provided shall be paid as set forth in each approved SOW and paid in US
Dollars. Consultant shall be paid for actual Services completed. 
 2.2 Consultant shall be reimbursed for all reasonable,
appropriate, or necessary travel and other out-of-pocket expenses incurred in the performance of its duties hereunder upon submission and approval of written statements
and bills in accordance with the then regular reimbursement procedures of Company. Prior written consent of Company is required for any expenses in excess of $1,000.00. Company or its authorized agents shall have the right to audit relevant
financial documentation to verify amounts billed at any time upon request by Company. 

  
 Invivyd, Inc. - Consulting Agreement

 2.3 Unless requested otherwise by the Company or its agents, Consultant shall submit
monthly invoices to Invivyd. All invoices submitted by Consultant to Invivyd under this Agreement shall (i) be sufficiently detailed, include a description of all Services performed and the amount due for the Services, (ii) reference the
applicable engagement, (iii) be clearly marked as an “Invoice”, and (iv) contain an invoice number. The invoice submitted by Consultant shall also include an itemized list of any expenses incurred in performance of the Services
under the Agreement and all documentation for expenses. If the Company provides Consultant an expense form to complete in connection with the Services performed, this form must be completed by Consultant and submitted to the Company as part of the
invoice. The Company shall pay the amount of each invoice received from Consultant within forty-five (45) days of its receipt by the Company, unless the Company has notified consultant within such forty-five (45) day period that it
disputes any particular invoiced item(s), which dispute the parties shall attempt in good faith to resolve. The Company reserves the right to decline to pay on invoices more than ninety (90) days after an expense has been incurred. In no event
will the Company pay on invoices submitted more than one hundred eighty (180) days after an expense has been incurred. All invoices shall be emailed to: AP@Invivyd.com for processing. The payment thereof shall constitute full
payment for Services to Company during the term of this Agreement, and Consultant shall not receive any additional benefits or compensation for the Services. Payment for Services performed under this Agreement shall be subject to the completion of
such Services to the reasonable satisfaction of Company. 
 2.4 At such times and intervals as Company may require, Consultant shall
provide Company with timely reports (and supporting documentation, if requested) of any payments made to health care providers, including, but not limited to, physicians, nurses, hospitals, pharmacies and health plans, in connection with
Consultant’s performance of the Services hereunder to allow Company to meet applicable federal and/or state law reporting requirements. Reportable payments shall include, but are not limited to, fees or honoraria paid for services, meals
provided and reimbursed travel, lodging and meals expenses. Consultant consents to Company’s disclosure of such fees and expenses from time to time, if and when required by law or government regulation thereunder, without any further
notification to Consultant. 
 3. INDEPENDENT CONTRACTOR RELATIONSHIP. Consultant’s
relationship with Company will be that of an independent contractor and nothing in this Agreement should be construed to create a partnership, joint venture, or employer-employee relationship. Consultant is not the agent of Company and is not
authorized to make any representation, contract, or commitment on behalf of Company. Consultant is not entitled to and will be excluded from participating in any of Company’s fringe benefit plans or programs as a result of the performance of
the Services, including, but not limited to, health, sickness, accident or dental coverage, life insurance, disability benefits, accidental death and dismemberment coverage, unemployment insurance coverage, workers’ compensation coverage, and
pension or 401(k) benefit(s) provided by Company to its employees (and Consultant waives the right to receive any such benefits). Consultant agrees, as an independent contractor, that Consultant is not entitled to unemployment benefits in the event
this Agreement terminates, or workers’ compensation benefits from Company in the event Consultant is injured in any manner or becomes ill while performing the Services under this Agreement. Consultant will be solely responsible for all tax
returns and payments required to be filed with or made to any federal, state or local tax authority with respect to Consultant’s performance of Services and receipt of fees under this Agreement. Consultant agrees to accept exclusive liability
for complying with all applicable state and federal laws governing self-employed individuals, including obligations such as payment of taxes, social security, disability and other contributions based on fees paid to Consultant, its agents or
employees under this Agreement. 

  
 2 

 4. INSURANCE. Consultant is responsible for providing and maintaining during
the term of this Agreement all appropriate insurance coverage required by applicable federal and state laws and shall produce a certificate of such insurance at Company’s request. 

5. CONFLICTS OF INTEREST. Consultant represents and warrants that he or she is
authorized to enter into this Agreement and is not a party to any other agreement or under any obligation to any third party which would prevent Consultant from entering into this Agreement or from performing Consultant’s obligation hereunder.
Consultant further represents and warrants that there is no conflict of interest in Consultant’s other contracts for services or other employment, if any, with the Services to be provided pursuant to this Agreement and that Consultant will
ensure that no such conflict arises during the term of this Agreement. If required to do so, Consultant has obtained all consents or permissions to enter into this Agreement. 

6. CONFIDENTIAL INFORMATION. 

6.1 Company Confidential Information. Consultant agrees during the term of this Agreement and thereafter that Consultant will
take all steps reasonably necessary to hold Company’s Confidential Information (as defined below) in trust and confidence, will not use Confidential Information in any manner or for any purpose not expressly set forth in this Agreement, and
will not disclose any such Confidential Information to any third party without first obtaining Company’s express written consent on a case-by-case basis. Consultant
will have its directors, officers, employees, collaborators, and agents (“Personnel”) who have access to Confidential Information enter into confidentiality obligations that are substantially similar to this Agreement. Consultant
shall be responsible for any breach of this Agreement by Consultant’s Personnel. Consultant shall notify Company immediately in writing upon any loss, misuse, misappropriation or other unauthorized disclosure of Company Confidential Information
by Consultant or Consultant’s Personnel. “Confidential Information” means any oral, written, graphic or machine-readable information including, but not limited to: that which relates to patents, patent applications, trade
secrets, inventions; research; product plans, products, developments, processes, designs, drawings, engineering, formulae; markets, regulatory information, medical reports; all clinical data and analysis and current and concluded clinical trials and
studies; reagents, cell lines, genes, gene haplotypes and gene sequences, assays, biological materials, chemical formulas, chemical compounds; business plans, agreements with third parties, services, customers, marketing or finances of Company or
other scientific, technical, financial, trade, or business information, of which Confidential Information is designated in writing or marked as being confidential or proprietary, or is disclosed under conditions that reasonably indicate that Company
intended such information to be confidential. Notwithstanding the other provisions of this Agreement, Confidential Information shall not include information that Consultant can demonstrate by competent written evidence: (i) has been published
or is otherwise readily available to the public other than by a breach of this Agreement; (ii) is known by Consultant at the time of receiving such information, as evidenced by Consultant’s
pre-existing written records; (iii) has been received by Consultant from a third party as a matter of right and without confidentiality limitations; or (iv) is independently developed by Consultant
without aid, use or benefit of Confidential Information. Notwithstanding the provisions of this Section 6.1, Consultant may disclose Confidential Information, without violating its obligations under this Agreement, to the
extent the disclosure is required by a valid order of a court or other governmental body of competent jurisdiction or is otherwise required by law or regulation, provided, that, Consultant shall give reasonable prior written notice to
Company of such required disclosure and, at Company’s request and expense, shall cooperate with Company’s efforts to contest such requirement, to obtain a protective order requiring that the Confidential Information so disclosed be used
only for the purposes for which the order was issued or the law or regulation required, and/or to obtain other confidential treatment of such Confidential Information. In any event, Consultant shall disclose only that portion of the Confidential
Information that is legally required to be disclosed. 

  
 3 

 6.2 Third Party Information. Consultant understands that Company has received and
will in the future receive from third parties confidential or proprietary information (“Third Party Information”) subject to a duty on Company’s part to maintain the confidentiality of such information and use it only for
certain limited purposes. Consultant agrees to hold Third Party Information in confidence and not to disclose to anyone (other than Company personnel who need to know such information in connection with their work for Company) or to use, except in
connection with Consultant’s work for Company, Third Party Information unless expressly authorized in writing by an officer of Company. 

6.3 Confidential Information of Others. Consultant agrees not to disclose to Company, bring onto Company’s premises, or induce
Company to use any confidential information that belongs to anyone other than Company or Consultant. The performance by Consultant of the Services does not and will not breach any agreement which obligates Consultant to keep in confidence any
confidential or proprietary information of any third party or to refrain from competing, directly or indirectly, with the business of any third party. Additionally, Consultant represents and warrants that Consultant’s performance of the
Services hereunder does and will not infringe upon any patient privacy or intellectual property rights. 
 6.4 Securities Laws. United
States securities laws prohibit any person who is given access to material, non-public information concerning a publicly traded company from purchasing or selling securities in that company or from
communicating the information to any other person who is likely to purchase or sell securities of that company. In connection with this Agreement, Consultant may have access to information that is considered material,
non-public information and Consultant agrees not to use, or cause any other person to use, such information to purchase or sell securities in any publicly traded company. 

7. WORK PRODUCT AND INTELLECTUAL PROPERTY RIGHTS. 

7.1 Disclosure of Work Product. As used in this Agreement, the term “Work Product” includes, but is not limited to, any
trade secrets, ideas, inventions (whether patentable or unpatentable), chemical and biological materials, samples of assay components, mask works, processes, procedures, formulations, formulas, software source and object codes, data, programs, other
works of authorship, know-how, improvements, discoveries, developments, designs and techniques, trademarks, manufacturing techniques, clinical trial designs or other copyrightable or patentable works.
Consultant agrees to disclose promptly in writing to Company, or any person designated by Company, all Work Product which is solely or jointly conceived, made, reduced to practice, or learned by Consultant in the course of any work or Services
performed for Company (“Company Work Product”). 
 7.2 Assignment of Company Work Product. Consultant irrevocably
assigns to Company all right, title and interest worldwide in and to the Company Work Product and all applicable intellectual property rights related to the Company Work Product, including without limitation, copyrights, trademarks, trade secrets,
patents, moral rights, contract and licensing rights (the “Proprietary Rights”). Consultant represents and warrants that Consultant Personnel performing any of the Services hereunder are obligated, pursuant to written agreement, to
assign to Consultant any rights that they may have in any Company Work Product, such that Consultant is able to assign such rights to Company hereunder. 

7.3 No Conflicting Obligations. Consultant agrees that he or she will not perform any Services for Company which would conflict with any
agreement or obligation of Consultant or which would cause or result in any other person or entity having any ownership interest in any intellectual property of Company, and will promptly notify Company in writing in the event that any proposed
Services may conflict with any such agreement or obligation, or result in such person or entity having any ownership interest. 

  
 4 

 7.4 Waiver or Assignment of Other Rights. If Consultant has any rights to Company
Work Product that cannot be assigned to Company, Consultant unconditionally and irrevocably waives the enforcement of such rights, and all claims and causes of action of any kind against Company with respect to such rights, and agrees, at
Company’s request and expense, to consent to and join in any action to enforce such rights. If Consultant has any right to the Company Work Product that cannot be assigned to Company or waived by Consultant, Consultant unconditionally and
irrevocably grants to Company during the term of such rights, an exclusive, irrevocable, perpetual, worldwide, fully paid and royalty-free license, with rights to sublicense through multiple levels of sublicensees, to reproduce, create derivative
works of, distribute, publicly perform and publicly display by all means now known or later developed, such rights. 
 7.5
Procurement and Enforcement of Proprietary Rights. Consultant will assist Company, both during and after the term of this Agreement, in procuring, maintaining and enforcing any United States and foreign Proprietary Rights relating to
Company Work Product in any and all countries. To that end Consultant will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Company may reasonably request for use in applying for,
obtaining, perfecting, evidencing, sustaining and enforcing such Proprietary Rights and the assignment thereof. In addition, Consultant will execute, verify and deliver assignments of such Proprietary Rights to Company or its designee.
Consultant’s obligation to assist Company with respect to Proprietary Rights relating to such Company Work Product in any and all countries shall continue beyond the termination of this Agreement, but Company shall compensate Consultant at a
reasonable rate after such termination for the time actually spent by Consultant at Company’s request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure Consultant’s signature on any
document needed in connection with the actions specified in this Section 7.5, Consultant hereby irrevocably designates and appoints Company and its duly authorized officers and agents as its agent and attorney in fact,
which appointment is coupled with an interest, to act for and in its behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and
effect as if executed by Consultant. 
 7.6 Consultant Property. Consultant will, however, retain full ownership rights in and to all
templates, programs and other materials developed by Consultant or obtained or licensed from third parties by Consultant (“Consultant Property”) prior to or independent of the Services and without use of or reliance upon Company’s
Confidential Information, regardless of whether such Consultant Property is used in the performance of the Services. Consultant hereby grants to Company a perpetual, non-exclusive, royalty-free, irrevocable,
fully paid-up worldwide license to use Consultant Property solely to the extent required for Company’s use of the Company Work Products. 

8. CONSULTANT REPRESENTATIONS AND WARRANTIES. 

8.1 Consultant hereby represents and warrants that (a) the Company Work Product will be an original work of Consultant and any
third parties will have executed assignment of rights reasonably acceptable to Company; (b) neither the Company Work Product nor any element thereof will infringe the Proprietary Rights of any third party; (c) neither the Company Work
Product nor any element thereof will be subject to any restrictions or to any mortgages, liens, pledges, security interests, encumbrances or encroachments; (d) Consultant will not grant, directly or indirectly, any rights or interest whatsoever
in the Company Work Product to third parties; (e) Consultant has full right and power to enter into and perform this Agreement without the consent of any third party; and (f) Consultant will take all necessary precautions to prevent injury
to any persons (including employees of Company) or damage to property (including Company’s property) during the term of this Agreement. 

  
 5 

 8.2 Consultant shall ensure that all statements and claims regarding Company’s
products made or proposed by Consultant in connection with the Services, including intended use, efficacy and safety, are consistent with Applicable Laws and the requirements of any applicable Regulatory Authority (as defined below) and are
accurate, truthful and fairly balanced. Consultant shall not make any representation, statement, warranty or guaranty, oral or written, with respect to any Company product that is inconsistent with Applicable Laws or such applicable Regulatory
Authority, that is deceptive or misleading in any way, or that disparages Company or any Company product. “Regulatory Authority” means any United States federal, state, or local government, or political subdivision thereof, or any
authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof), or any governmental
arbitrator or arbitral body with responsibility for granting approvals necessary for the marketing of or having other legal or regulatory authority over a product of Company involved in the Services, including the U.S. Food and Drug Administration.

 8.3 Consultant represents and warrants that neither Consultant nor any of Consultant’s Personnel used in connection with the
Services is Debarred/Excluded (as defined below). In advance of any Consultant Personnel performing any Services under this Agreement, Consultant shall check the Debarment/Exclusion status of each such Consultant Personnel and confirm that such
Consultant Personnel is not Debarred/Excluded and shall confirm such status at least annually thereafter. Upon discovering that Consultant or any Consultant Personnel is Debarred/Excluded, Consultant shall immediately notify Company and remove such
Consultant Personnel from having any responsibilities relating to the Services. “Debarred/Excluded” means debarred or suspended under 21 U.S.C. §335(a) or (b), excluded from participation in a federal health care program (e.g.,
Medicare, Medicaid), debarred from federal contracting, or convicted of or pled nolo contendere to any felony or any federal or state legal violation (including misdemeanors) relating to health care products or services or fraud.

8.4 If, during the term of this Agreement, all or part of the above representations and warranties in this
Section 8 cease to be accurate, Consultant shall immediately notify Company of such circumstance, and, at Company’s option, this Agreement shall terminate as of the first date of such noncompliance. 

9. NOTICE OF GOVERNMENT INQUIRY. Consultant shall immediately notify Company, and
provide Company with a copy, of any communication, correspondence or inquiry of any type, including, but not limited to, a subpoena, civil investigative demand, congressional inquiry letter, untitled letter or warning letter, from any federal, state
or local governmental entity, Regulatory Authority or any other individual or party related in any way to Company, Company’s products, the Services, or this Agreement. This Section survives expiration or termination of the Agreement. 

10. INDEMNIFICATION. Consultant will indemnify and hold harmless Company, its officers, directors, employees, sublicensees,
customers and agents from any and all claims, losses, liabilities, damages, expenses and costs (including attorneys’ fees and court costs) which result from and with respect to any and all third-party claims of any kind based on (i) any
act or omission or willful misconduct of Consultant or any of Consultant’s Personnel under or in connection with Consultant’s obligations hereunder; (ii) a breach or alleged breach of any representation or warranty of Consultant set
forth in Section 8 of this Agreement; or (iii) any infringement of any patent, trade secret, copyright, trademark or any other proprietary right of any person by the Company’s use of the Company Work Product. 

  
 6 

 11. TERM AND TERMINATION. 

11.1 Term. The term of this Agreement will begin effective as of October 13, 2022 and will continue until terminated in
accordance with this Agreement. Notwithstanding the foregoing, this Agreement shall not expire, but shall continue in full force and effect until Consultant’s completion of any unperformed obligations under any SOW executed prior to the date
upon which the Agreement would otherwise have expired. During the Term and for a period of one (1) year thereafter, Consultant shall not, without Company’s prior written approval, perform any Services for any third party that develops or
commercializes products directly in competition with any Company product that is related to a SOW or Services performed thereunder. 

11.2 Termination by Company. Company may terminate this Agreement or any SOW at its convenience and without any breach by
Consultant upon ten (10) days’ prior written notice to Consultant. Company may also terminate this Agreement immediately in its sole discretion if Consultant refuses to, or is unable to, perform or is otherwise in default in its
performance of, the Services or is in breach of any material provision of this Agreement. 
 11.3 Termination by Consultant.
Consultant may terminate this Agreement or any SOW upon thirty (30) days’ prior written notice to Company. 
 11.4 Return of
Company Property. Immediately upon notice of termination of the Agreement (or earlier if requested by Company), Consultant shall cease work and deliver to Company any and all (including copies thereof) work in progress, Company-owned materials
and/or equipment, including all material containing or disclosing any Company Work Product, Third Party Information or Company Confidential Information. 

12. GENERAL PROVISIONS. 

12.1 Governing Law. This Agreement will be governed and construed in accordance with the laws of the Commonwealth of Massachusetts, USA,
without regard to any conflict of laws principles that would result in the application of the laws of any other jurisdiction. Consultant hereby expressly consents to the personal jurisdiction of the state and federal courts located in Massachusetts
for any lawsuit filed there against Consultant by Company arising from or related to this Agreement. 
 12.2 Non-solicitation. Consultant agrees that during the term of this Agreement, and for one year thereafter, Consultant will not either directly or indirectly, solicit or attempt to solicit any employee, independent
contractor, or consultant of Company to terminate his, her, its or their relationship with Company in order to become an employee, consultant, or independent contractor to or for any other person or entity. 

12.3 Severability. In case any one or more of the provisions contained in this Agreement shall, for any reason, be held to be invalid,
illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never
been contained herein. If moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it shall be construed by limiting and
reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear. 

  
 7 

 12.4 No Assignment; Subcontracting. This Agreement may not be assigned by Consultant
without Company’s consent, and any such attempted assignment shall be void and of no effect. Consultant may not subcontract or otherwise delegate its obligations under this Agreement without Company’s prior written consent, which consent
may be withheld in Company’s sole discretion. 
 12.5 Notices. All notices, requests and other communications under this
Agreement must be in writing, and must be mailed by registered or certified mail, postage prepaid and return receipt requested, or delivered by hand to the party to whom such notice is required or permitted to be given. If mailed, any such notice
will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark. If delivered by hand, any such notice will be considered to have been given when received by the party to whom notice is given, as
evidenced by written and dated receipt of the receiving party. The mailing address for notice to either party will be the address shown on the signature page of this Agreement. Either party may change its mailing address by notice as provided by
this Section 12.5. 
 12.6 Injunctive Relief. A breach of any of the promises or agreements contained in
this Agreement may result in irreparable and continuing damage to Company for which there may be no adequate remedy at law, and Company is therefore entitled to seek injunctive relief as well as such other and further relief as may be appropriate.

 12.7 Survival. The following provisions shall survive expiration or termination of this Agreement: Sections 6 through
12. 
 12.8 Waiver. No waiver by Company of any breach of this Agreement shall be a waiver of any preceding or succeeding
breach. No waiver by Company of any right under this Agreement shall be construed as a waiver of any other right. Company shall not be required to give notice to enforce strict adherence to all terms of this Agreement. 

12.9 Entire Agreement. This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter
hereof and supersedes and merges all prior discussions between the parties. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing and signed by the party to be
charged. The terms of this Agreement will govern all Services undertaken by Consultant for Company. 
 12.10 Execution in Counterparts;
Electronic Signatures. This Agreement may be executed in two or more counterparts, each of which will be an original, and all of which together will constitute one and the same instrument. The parties agree that electronic signatures shall be
deemed originals. 
 [Signature page follows] 

  
 8 

 

 
  

 IN WITNESS WHEREOF, the parties have
caused this Consulting Services Agreement to be executed by their duly authorized representative. 
  

			
	COMPANY:
	
	INVIVYD, INC.
		
	By:	 	 /s/ Julie Green

	Name: Julie Green
	Title: Senior Vice President, Human Resources
	
	CONSULTANT:
		
	By:	 	 /s/ Fred Driscoll

	Name: Fred Driscoll

 

 
  

 EXHIBIT A 

STATEMENT OF WORK #1 
 This Statement of
Work #1 (“SOW #1”), effective as of October 13, 2022 (the “Effective Date”), is made by and between INVIVYD, INC., a Delaware corporation and its successors or assignees (“Company”) and
Fred Driscoll. (“Consultant”). 
 Consultant and Company are parties to that certain Consulting Services Agreement, effective as of
October 13, 2022 (the “Agreement”). Consultant shall perform for Company the services specifically described herein (the “Services”). This SOW #1 is incorporated into the Agreement and expressly made a
part thereof and, thus, subject to the terms and conditions of the Agreement. 
 SERVICES 

The Services shall include duties and responsibilities of an interim Chief Financial Officer, or other services reasonably requested by the CEO or the Board

 FEES 
 Cash Fee:
Consultant’s fee for the Services provided under this SOW #1 shall be $50,000 per month. 
 Reimbursements: Consultant shall submit an
invoice to Company related to the Services provided to Company and any appropriate, reimbursable expenses. Company will issue payment for the invoice within forty-five (45) days of receipt of an invoice. All invoices shall be submitted and paid
in accordance with Section 2.3 of the Agreement. 
 [Signature page follows] 

 IN WITNESS WHEREOF, the
parties have caused this Statement of Work #1 to be executed by their duly authorized representative. 
  

			
	COMPANY:
	
	INVIVYD, INC.
		
	By:	 	 /s/ Julie Green

	Name: Julie Green
	Title: Senior Vice President, Human Resources
	
	CONSULTANT:
		
	By:	 	 /s/ Fred Driscoll

	Name: Fred Driscoll

  
 2Document

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934
As of August 31, 2022, Commercial Metals Company (“CMC,” the “Company,” “we,” “us,” and “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, $0.01 par value per share (the “Common Stock”).
Description of Capital Stock
The following summary of our capital stock does not purport to be complete and is subject to and qualified in its entirety by reference to our Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), including the certificates of designations pursuant to which any outstanding series of preferred stock may be issued, our Amended and Restated Bylaws, or any supplement or amendment thereto (the “Bylaws”), and the General Corporation Law of the State of Delaware (“DGCL”). Copies of our Certificate of Incorporation and Bylaws have been filed with the Securities and Exchange Commission as Exhibits 3(i)(a)-(f) and 3(ii), respectively, to our Annual Report on Form 10-K.
Authorized Capital Stock
Under the Certificate of Incorporation, our authorized capital stock consists of:
•two hundred million (200,000,000) shares of Common Stock, par value $0.01 per share, and
•two million (2,000,000) shares of preferred stock, par value $1.00 per share.
As of August 31, 2022, we had approximately 117,496,053 shares of Common Stock outstanding and no shares of preferred stock outstanding. As of August 31, 2022, we had reserved approximately 5,882,340 additional shares of Common Stock for issuance under our various stock and compensation incentive plans.
Common Stock
Dividend Rights
Holders of Common Stock are entitled to receive dividends when, as and if declared by the Company’s board of directors (the “Board of Directors”), out of funds legally available for their payment (subject to the rights of holders of the preferred stock, if any). 
Voting Rights
Except as otherwise required by law, the Certificate of Incorporation or the Bylaws, each holder of Common Stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders of the Company, including the election of directors. The holders of Common Stock do not have cumulative voting rights. 
Liquidation Rights
In the event of our voluntary or involuntary liquidation, dissolution or winding up, the holders of Common Stock will be entitled to share ratably in any of our assets available for distribution after the payment in full of all debts and distributions and after the holders of all series of outstanding preferred stock, if any, have received their liquidation preferences in full.
Miscellaneous
Holders of Common Stock have no sinking fund or redemption provisions, or conversion or preemptive rights. All outstanding shares of Common Stock are validly issued, fully paid and non-assessable. 
Exchange Listing
The Common Stock is listed on the New York Stock Exchange under the symbol “CMC.”
Transfer Agent

The transfer agent for our Common Stock is Broadridge Corporate Issuer Solutions, Inc.
Preferred Stock
The Company is authorized to issue preferred stock from time to time, in one or more series with such rights, preferences, privileges and restrictions, including dividend rights, voting rights, conversion rights, terms of redemption and liquidation preferences as may be fixed or designated by the Board of Directors without any further vote or action by the stockholders. Under certain circumstances, the issuance of preferred stock may discourage or make more difficult a merger, tender offer, other business combination or proxy contest, the assumption of control by a holder of a large block of the Company’s securities or the removal of incumbent management even if such event were favorable to the interests of stockholders. The Board of Directors, without stockholder approval, may issue preferred stock with voting and conversion rights and dividends and liquidation preferences which could adversely affect the holders of Common Stock. As of August 31, 2022, there are no shares of preferred stock outstanding.
Certain Provisions of the Certificate of Incorporation and Bylaws
The Certificate of Incorporation and Bylaws of the Company contain certain provisions that may delay, defer or prevent a change in control of the Company.
Classified Board; Vacancies and Removal of Directors
    Our Certificate of Incorporation and Bylaws classify the Board of Directors into three classes of directors as nearly equal in number as possible, with members of each class serving staggered three-year terms and one class of directors being elected each year.
Our Certificate of Incorporation and Bylaws provide that directors may be removed only for cause (generally defined to include conviction of a felony, failure to attend 12 consecutive Board of Directors meetings, or negligence or misconduct in the performance of the duties of a director) and only with the approval of the holders of at least a majority of the voting power of the then-outstanding shares of any class or series of the Company’s capital stock entitled to vote generally in the election of directors (the “Voting Stock”). The number of directors shall be fixed and modified, but not reduced to less than three, from time to time by resolution of a majority of the authorized directors our Board of Directors. Newly created directorships resulting from an increase in the number of directors and any vacancy on the Board of Directors may be filled by the majority vote of the remaining directors then in office, though less than a quorum, and directors so elected shall hold office for a term expiring when the class to which they have been elected expires.

Stockholder Action by Written Consent
    Our Certificate of Incorporation and Bylaws provide that any action taken by the stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by written consent.
Special Meetings
Our Certificate of Incorporation and Bylaws provide that special meetings of our stockholders may be called only by the Board of Directors pursuant to a resolution adopted by a majority of the entire Board of Directors, by stockholders owning not less than a majority of the Voting Stock or by The Jacob Feldman and Sara B. Feldman Grantor Trust dated September 24, 1985 and the trustees of that trust if the Trust owns at least 10% of the Voting Stock. Our Bylaws contain detailed instructions regarding special meeting requests by stockholders, including requesting meeting dates and the content of such notices. The Board of Directors may postpone, reschedule or cancel any special meeting of the stockholders called by the Board of Directors.

Advance Notice Requirement
Our Bylaws set forth advance notice procedures with regard to stockholder nomination of persons for election to the Board of Directors or other business to be considered at an annual meeting of stockholders. These procedures provide that notice of such stockholder proposals must be timely given in writing to the secretary of the Company prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received by the secretary at the principal executive offices of the Company not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the anniversary date of the immediately preceding annual meeting of stockholders. Our Bylaws also specify the form and content of a stockholder’s notice. The advance notice requirement does not give the Board of Directors any power to 

approve or disapprove stockholder director nominations or proposals but may have the effect of precluding the consideration of certain business at a meeting if the proper notice procedures are not followed. 
In addition, our Bylaws contain “proxy access” provisions, which permit a stockholder, or a group of up to 20 stockholders, that has continuously owned for no less than three years at least 3% of the Company’s outstanding shares of common stock, to nominate and include in the Company’s proxy materials up to the greater of two directors and 20% of the number of directors currently serving on the Company’s board, provided that the stockholder(s) and the nominee(s) satisfy the requirements specified in the Bylaws. 
Limitation of Liability of Directors
The Certificate of Incorporation generally provides that, to the fullest extent permitted by the DGCL, no director shall be liable to the Company or its stockholders for monetary damages for breach of certain fiduciary duties as a director. Under the DGCL, a director’s liability may not be eliminated:
•for any breach(es) of the director’s duty of loyalty to us or to our stockholders;
•for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
•for certain unlawful dividend payments or stock redemptions or repurchases; and
•for any transaction from which the director derives an improper personal benefit.
The effect of this provision is to restrict the rights of the Company and its stockholders to recover monetary damages against a director for breach of certain fiduciary duties as a director.
Supermajority Voting
The affirmative vote of the holders of 70% or more of the outstanding shares of Voting Stock is required to alter, amend, repeal or adopt any provision inconsistent with the provisions of the Certificate of Incorporation and Bylaws relating to the number of directors, classified board, vacancy and removal of directors, right to call a special meeting and prohibition on stockholder action by written consent.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]